Kolexia
Chebrek Safia Hématologie
Chebrek Safia
Hématologie
Centre Hospitalier D’Avignon
Avignon, France
69 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie myéloïde Leucémie aigüe myéloïde Lymphomes Hypertension artérielle Tumeurs du système nerveux central Hypertension pulmonaire Éosinophilie Leucémie-lymphome lymphoblastique à précurseurs B et T

Collaborateurs

Voir plus
Slama Borhane
Slama Borhane
Centre Hospitalier D’Avignon, Avignon, France
Zerazhi Hacene
Zerazhi Hacene
Centre Hospitalier D’Avignon, Avignon, France
Boulat Olivier
Boulat Olivier
Centre Hospitalier D’Avignon, Avignon, France
Cloarec Nicolas
Cloarec Nicolas
Centre Hospitalier D’Avignon, Avignon, France

Industries

Voir plus
B3TSI
68 collaboration(s)
Dernière en 2023
A+A
10 collaboration(s)
Dernière en 2021
Novartis
9 collaboration(s)
Dernière en 2023
Janssen
9 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
ALFA2101: An ALFA 2101 Multicenter Randomized Phase II Study: CPX-351 Versus Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Essai Clinique (CHU Nice)   29 janvier 2024
IPA-LMC: Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia
Essai Clinique (Centre Hospitalier D’Avignon)   29 novembre 2023
Involvement of the JAK-STAT Pathway in the Molecular Landscape of Fusion-Free Myeloid Neoplasms with Eosinophilia
65th ASH Annual Meeting Abstracts   02 novembre 2023
CPX-351 in Patients with Newly Diagnosed Post Myeloproliferative Neoplasms Acute Myeloid Leukemia
65th ASH Annual Meeting Abstracts   02 novembre 2023
Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report
65th ASH Annual Meeting Abstracts   02 novembre 2023
LAMSA2020: A Phase II Randomized Study to Assess the Efficacy on Outcome of Venetoclax Combined With Cytarabine Versus Idarubicin Combined With Cytarabine Administered as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission
Essai Clinique (French Innovative Leukemia Organisation)   07 septembre 2023
STAIR: STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia
Essai Clinique (French Innovative Leukemia Organisation)   23 mai 2023
Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
Annual Meeting Abstracts 2022   15 novembre 2022
Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study
Annual Meeting Abstracts 2022   15 novembre 2022
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
Leukemia   14 novembre 2022